Raviteja Guddeti, MD
Interventional Cardiology · Cincinnati, OHNPI 1891101986
Payments from drug & device makers
What this record shows
This record is dominated by grants: $60,000 of the $67,964 with a category attached, or 88.3%. 17 manufacturers reported payments, led by Abbott at 35.0% of the total. Reporting peaked in 2024 at $62,506 and has fallen 93.7% since, to $3,947 in 2025.
Across 85 payments — averaging $799.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$24K
- Medtronic$21K
- Boston Scientific$20K
- Edwards Lifesciences$2K
- Teleflex LLC$368
- Jenavalve Technology, Inc.$175
- plus $719 from 11 others
What the payments were for
- Consulting fees$2,4004%
- Grants$60,00088%
- Travel & lodging$2,9544%
- Food & beverage$2,6104%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 15 | $23,783 |
| Medtronic | 15 | $21,072 |
| Boston Scientific | 6 | $20,259 |
| Edwards Lifesciences | 18 | $1,587 |
| Teleflex LLC | 3 | $368 |
| Jenavalve Technology, Inc. | 1 | $175 |
| Cardiovascular Systems Inc. | 2 | $171 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $146 |
| Abiomed | 2 | $126 |
| Amgen | 4 | $69 |
| Boehringer Ingelheim | 2 | $46 |
| AstraZeneca | 2 | $37 |
| Novartis | 2 | $32 |
| Merck | 2 | $28 |
| Philips North America LLC | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$20,668
- NAVITOR$2,400
- PASCAL$1,165
- TRICLIP$1,028
- MitraClip$162
- Diamondback Coronary$142
- TRAPLINER$140
- TURNPIKE$131
- AVVIGO Guidance System$113
- Impella$103
How this compares
$67,964 in reported general payments places this provider in the 85th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 86 | $69,535 |
| EntrestoSacubitril/Valsartan | 41 | $36,207 |
| FarxigaDapagliflozin Propanediol | 36 | $23,700 |
| BrilintaTicagrelor | 13 | $16,704 |
| JardianceEmpagliflozin | 19 | $13,540 |
| XareltoRivaroxaban | 17 | $9,672 |
| Metoprolol Succinate | 136 | $1,033 |
| ClopidogrelClopidogrel Bisulfate | 100 | $842 |
| Rosuvastatin Calcium | 39 | $621 |
| Atorvastatin Calcium | 76 | $604 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 14 | $494 |
| Furosemide | 84 | $322 |
| Carvedilol | 40 | $220 |
| Ezetimibe | 13 | $205 |
| Potassium Chloride | 11 | $203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $37 | $40,40349 claims |
| NovartisEntresto | $32 | $36,20741 claims |
| Boehringer IngelheimJardiance | $46 | $13,54019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Cincinnati
- Timothy HenryCincinnati$605K
- John CorlCincinnati$390K
- Santiago GarciaCincinnati$360K
- Joseph ChooCincinnati$224K
- Dean KereiakesCincinnati$139K
- Ian SarembockCincinnati$98K
- Puvi SeshiahCincinnati$81K
- Satya ShreenivasCincinnati$47K
- Amer SayedCincinnati$31K
- Zaid AlirhayimCincinnati$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.